FDA Approves Outlook Therapeutics’ Lytenava for Wet AMD, Delivering the First Dedicated Ophthalmic Bevacizumab to Retina Care

Published: July 25, 2026

WASHINGTON — In a major milestone for retina care, the U.S. Food and Drug Administration (FDA) has approved Outlook Therapeutics’ Lytenava (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (wet AMD). Announced on July 24, 2026, the approval grants the New Jersey-based biopharmaceutical firm its first U.S. commercial clearance and provides retina specialists with the first purpose-built, FDA-sanctioned ophthalmic formulation of bevacizumab.

The decision concludes a multi-year regulatory saga marked by three previous Complete Response Letters (CRLs) and a successful formal appeal to the FDA’s Office of New Drugs. Outlook Therapeutics plans to launch the drug commercially in the United States before the end of the year, supported by an anticipated 12 years of market exclusivity under federal biologics regulations.

Understanding Wet AMD: A Race Against Irreversible Vision Loss

Age-related macular degeneration is a leading cause of severe, permanent vision loss among adults aged 50 and older. While the “dry” form of AMD accounts for the majority of cases, approximately 10% to 15% progress to neovascular or “wet” AMD.

In wet AMD, abnormally fragile blood vessels sprout beneath the retina. These vessels leak fluid and blood into the macula—the central area of the retina responsible for sharp, straight-ahead vision required for driving, reading, and recognizing faces. Left untreated, the fluid accumulation leads to scarring and rapid visual decline.

An Analogy for the Retina: Think of the retina as a camera sensor. In wet AMD, abnormal blood vessels act like leaky pipes underneath that sensor. The accumulated moisture blurs and distorts the incoming picture. Anti-VEGF medications work by shutting off those leaks, stabilizing the visual image before permanent structural damage occurs.

How Lytenava Works

Lytenava belongs to a class of biological therapies known as vascular endothelial growth factor (VEGF) inhibitors. VEGF is a naturally occurring protein that signals the body to grow new blood vessels. In wet AMD, excess VEGF triggers the destructive vascular growth in the eye.

Administered via intravitreal injection (a quick procedure performed directly into the eye after numbing), bevacizumab-vikg binds to VEGF molecules, neutralizing their activity and suppressing further fluid leakage.

  +-----------------------------------------------------------------+
  |                    THE ANTI-VEGF MECHANISM                      |
  +-----------------------------------------------------------------+
  |  [Excess VEGF Protein] ---> Promotes leaky vessel growth       |
  |                                       │                         |
  |  [Lytenava / Bevacizumab-vikg] ───────┼──> Blocks VEGF Receptors |
  |                                       │                         |
  |  [Result] ───────────────────────────> Suppresses fluid leak,   |
  |                                            preserves central vision |
  +-----------------------------------------------------------------+

Ending 20 Years of Off-Label Compounding

For over two decades, ophthalmologists have relied heavily on off-label bevacizumab (sold under the brand name Avastin for oncology) as a cost-effective treatment for wet AMD. However, because Avastin was manufactured for intravenous cancer treatments in large vials, eye care practices had to rely on specialized compounding pharmacies to split the drug into tiny, sterile single-dose syringes for ocular injection.

While widely effective, off-label compounding carried inherent logistical challenges:

• Infection Risks: Historical instances of batch contamination at compounding facilities occasionally caused severe intraocular infections (endophthalmitis).

• Variability: Minor fluctuations in dosage, silicone oil contamination from syringes, and varying pH levels between compounding facilities.

• Lack of Direct Oversight: Off-label preparations lacked dedicated FDA-monitored manufacturing standards specific to ocular toxicity.

“The retina community has been waiting a long time for access to an FDA-approved, ophthalmic formulation of bevacizumab to treat patients suffering from wet AMD in the United States,” noted Dr. Firas M. Rahhal, Chairman of Ophthalmology at Good Samaritan Hospital in Los Angeles, in a statement accompanying the announcement.

Clinical Data and Regulatory Journey

The FDA’s decision follows a rigorous review path. Outlook’s clinical pipeline included the NORSE clinical trial series. Data from these pivotal studies evaluated the safety and efficacy of ONS-5010 (now Lytenava) compared to established anti-VEGF standard care, demonstrating significant reductions in central retinal thickness and stabilization of visual acuity.

Public Health Impact and Next Steps

The availability of a purpose-built, FDA-regulated bevacizumab formulation has broad public health implications for an aging population.

What This Means for Patients and Caregivers

1. Quality & Standardized Safety: Patients receive a drug manufactured in facilities specifically inspected for ophthalmic safety standards, reducing concerns around compounding variability.

2. Insurance & Access: FDA approval establishes dedicated billing codes, which may simplify coverage pathways and reimbursement support programs for retina clinics.

3. Sustained Treatment Choices: Having another branded anti-VEGF option ensures that patients who do not respond well to one drug have alternative options.

Trial Limitations & Considerations

It is important to note that while FDA approval verifies safety and efficacy, anti-VEGF therapy is not a cure for wet AMD. Treatment typically requires ongoing monitoring and repeat injections every few weeks or months to keep disease activity under control. Furthermore, full head-to-head durability metrics across diverse patient subgroups will continue to be monitored through post-market pharmacovigilance.

Patients experiencing visual changes, such as wavy lines or dark central spots, should consult a retina specialist immediately for a comprehensive dilated eye exam.

Scientific & Reference Documentation

Primary Citations

1. U.S. Food and Drug Administration / Outlook Therapeutics Press Release (July 24, 2026): “FDA Approves LYTENAVA (bevacizumab-vikg) for the Treatment of Wet Age-Related Macular Degeneration.”

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.